100 million covid shots in 100 days doesn’t get us back to normal
April 30 will mark the end of the first 100 days of President Joe Biden s tenure. That s a benchmark presidents often set for making good on high-priority campaign promises.
In early December, Biden announced that one promise would be to get 100 million covid-19 vaccines into the arms of Americans in the first 100 days, averaging about 1 million daily doses. The U.S. reached that pace around Inauguration Day but will have to maintain it for the next three months for Biden to reach his goal.
If realized, how will everyday life change? We asked the experts.
By
Feb 01, 2021 09:49 PM EST
As many people are very excited to share that they have gotten their COVID-19 vaccine already, the Better Business Bureau (BBB) has warned Americans not to post their COVID-19 vaccine cards on social media.
According to the BBB, a non-profit organization whose main goal is to expose fraudulent activity and provide consumers with information, people should avoid posting pictures of their vaccine cards since it may attract scammers who might take advantage of the information on the card.
In a news release, the bureau said vital personal information such as the person s full name, birthday, and where they got the vaccine is seen on the card. Thus it can be used as a source of information for fraud.
For many Americans, finally getting the COVID-19 vaccine can be exciting and a huge relief. But if you do receive it, don t go boasting about it on social media.
That s kind of what the Better Business Bureau is warning us about. They advise not to share photos of your COVID-19 vaccine cards on social media. Unfortunately, your card has your full name and birthday on it, as well as information about where you got your vaccine, said the BBB in a news release. If your social media privacy settings aren t set high, you may be giving valuable information away for anyone to use.
Feb 2, 2021
Reduced efficacy seen in South African strain
Johnson & Johnson’s single-shot Covid-19 vaccine candidate was shown to be very effective overall, but significantly less effective against the highly contagious South African B.1.351 variant of the disease predicted by many to become the dominant form of SARS-CoV-2 infection in the United States by mid-spring.
Data from the ENSEMBLE trial, released Friday morning, showed the vaccine to have a 72% overall efficacy in U.S., with a 66% overall effectiveness for preventing moderate-to-severe disease 28 days after vaccination.
Trial data from South Africa, where the B.1.351 variant was the predominant strain at the time of the study, showed the single-shot J&J-Janssen Pharmaceuticals vaccine to be 57% effective.
Johnson & Johnson one-dose COVID-19 shot offers strong protection, fuels concern about variants
A single-dose vaccine is a big advantage when most countries are struggling to get shots in arms more quickly.
Feb 01, 2021 14:57:16 IST
Johnson & Johnson, the only major drugmaker developing a single-dose vaccine for COVID, announced Friday that its shot provided strong protection against COVID-19, potentially offering another powerful tool in a desperate race against a worldwide rise in virus mutations. But the results came with a significant cautionary note: The vaccine’s efficacy rate dropped from 72% in the United States to 57% in South Africa, where a highly contagious variant is driving most cases.